Global Clostridium Difficile Treatment Market 2017-2021
About Clostridium Defficile Treatment
CDI is a bacterium that can cause symptoms such as diarrhea and life-threatening inflammation of the colon. CDI mostly affects elderly people who frequent hospitals or people who live in long-term care facilities. CDI can also occur due to the prolonged use of antibiotics. The first line of treatment for CDI is antibiotics.
Technavio’s analysts forecast the global clostridium defficile treatment market to grow at a CAGR of 5.14% during the period 2017-2021. Covered in this report
The report covers the present scenario and the growth prospects of the global clostridium defficile treatment market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
Technavio's report, Global Clostridium Defficile Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Clostridium Defficile Treatment Market 2017-2021
Technavio recognizes the following companies as the key players in the global clostridium defficile treatment market: Actelion Pharmaceuticals, Merck, Pfizer, and Summit Therapeutics.
Other Prominent Vendors in the market are: Astellas Pharma, CRESTOVO, Da Volterra, Immuron, MGB Biopharma, Novartis, Otsuka Pharmaceutical, Rebiotix, Romark Laboratories, Sanofi Pasteur, Seres Therapeutics, Shire, Synthetic Biologics, Valeant Pharmaceuticals, and Valneva.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is special designation. Special designations such as Fast Track and Qualified Infectious Disease Product (QIDP), which are provided by the FDA, will encourage vendors to launch new products. These designations are beneficial for the market as they will enable the quick completion of the clinical trial process.”
According to the report, one driver in the market is rise in aging population. As people age, their immune systems deteriorate. People above the age of 60 may experience several medical complications. Aging plays a significant role in the manifestation of CDI. Research studies estimate that people above the age of 60 are susceptible to CDI, with the median age of diagnosis being 70. The rise in the aging population will increase the number of people affected by CDI.
Further, the report states that one challenge in the market is high cost of therapy and high mortality rate. CDI requires constant monitoring and medication, which leads to the increased use of antibiotics. Considering these antibiotics are expensive and have several side effects, patients end up discontinuing treatment. This leads to reduced patient adherence and shrinking the market value. The morbidity, mortality, and medical care costs of CDI have been growing.
Actelion Pharmaceuticals, Merck, Pfizer, and Summit Therapeutics
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook